How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
48
FATE Quote, Financials, Valuation and Earnings
Last price:
$1.20
Seasonality move
:
8.67%
Day range:
$1.17 - $1.21
52-week range:
$0.66 - $1.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.08x
P/B ratio:
0.60x
Volume:
2.3M
Avg. volume:
1.7M
1-year change:
-6.92%
Market cap:
$139.6M
Revenue:
$13.6M
EPS (TTM):
-$1.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
$1.2M | -$0.27 | -35.58% | -38.02% | $4.94 |
|
ARDX
Ardelyx, Inc.
|
$118.5M | $0.01 | 44.75% | -49.9% | $14.20 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $5.12 | 14.78% | 93.57% | $506.64 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
$1.21 | $4.94 | $139.6M | -- | $0.00 | 0% | 20.08x |
|
ARDX
Ardelyx, Inc.
|
$7.86 | $14.20 | $1.9B | -- | $0.00 | 0% | 4.76x |
|
MNKD
MannKind Corp.
|
$5.64 | $9.61 | $1.7B | 59.87x | $0.00 | 0% | 5.55x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.00 | $0.85 | $252.3M | 3.36x | $0.80 | 0% | 3.89x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$477.91 | $506.64 | $121.3B | 33.68x | $0.00 | 0% | 10.55x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
25.29% | 1.072 | 54.53% | 7.69x |
|
ARDX
Ardelyx, Inc.
|
57.37% | -0.680 | 15.51% | 3.83x |
|
MNKD
MannKind Corp.
|
124.56% | -0.195 | 13.7% | 2.54x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.58% | -0.699 | 1.84% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
-$1.5M | -$34.7M | -41.23% | -53.28% | -1995.12% | -$26.6M |
|
ARDX
Ardelyx, Inc.
|
$105.4M | $4.7M | -17.69% | -36.67% | 4.23% | $209K |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.7B | $1.3B | 20.08% | 22.13% | 41.02% | $1.1B |
Fate Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FATE or ARDX?
Ardelyx, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of -0.88%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Ardelyx, Inc.'s return on equity of -36.67%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M ARDXArdelyx, Inc.95.57% -$0.00 $361.9M -
What do Analysts Say About FATE or ARDX?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 308.63%. On the other hand Ardelyx, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 80.66%. Given that Fate Therapeutics, Inc. has higher upside potential than Ardelyx, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Ardelyx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 ARDXArdelyx, Inc.10 0 0 -
Is FATE or ARDX More Risky?
Fate Therapeutics, Inc. has a beta of 2.223, which suggesting that the stock is 122.341% more volatile than S&P 500. In comparison Ardelyx, Inc. has a beta of 0.558, suggesting its less volatile than the S&P 500 by 44.163%.
-
Which is a Better Dividend Stock FATE or ARDX?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Ardelyx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or ARDX?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than Ardelyx, Inc. quarterly revenues of $110.3M. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Ardelyx, Inc.'s net income of -$969K. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Ardelyx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 20.08x versus 4.76x for Ardelyx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.20.08x -- $1.7M -$32.3M ARDXArdelyx, Inc.4.76x -- $110.3M -$969K
-
Which has Higher Returns FATE or MNKD?
MannKind Corp. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of 9.72%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About FATE or MNKD?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 308.63%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 70.41%. Given that Fate Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Fate Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 MNKDMannKind Corp.8 0 0 -
Is FATE or MNKD More Risky?
Fate Therapeutics, Inc. has a beta of 2.223, which suggesting that the stock is 122.341% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.
-
Which is a Better Dividend Stock FATE or MNKD?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or MNKD?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than MannKind Corp.'s net income of $8M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 59.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 20.08x versus 5.55x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.20.08x -- $1.7M -$32.3M MNKDMannKind Corp.5.55x 59.87x $82.1M $8M
-
Which has Higher Returns FATE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of -255.85%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About FATE or NBY?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 308.63%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -57.5%. Given that Fate Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is FATE or NBY More Risky?
Fate Therapeutics, Inc. has a beta of 2.223, which suggesting that the stock is 122.341% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock FATE or NBY?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or NBY?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 20.08x versus 3.89x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.20.08x -- $1.7M -$32.3M NBYNovaBay Pharmaceuticals, Inc.3.89x 3.36x $521K -$1.3M
-
Which has Higher Returns FATE or PTN?
Palatin Technologies has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of --. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About FATE or PTN?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 308.63%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Fate Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Fate Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 PTNPalatin Technologies0 0 0 -
Is FATE or PTN More Risky?
Fate Therapeutics, Inc. has a beta of 2.223, which suggesting that the stock is 122.341% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock FATE or PTN?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or PTN?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than Palatin Technologies quarterly revenues of --. Fate Therapeutics, Inc.'s net income of -$32.3M is higher than Palatin Technologies's net income of --. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 20.08x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.20.08x -- $1.7M -$32.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns FATE or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of 34.76%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M VRTXVertex Pharmaceuticals, Inc.86.69% $4.20 $19.2B -
What do Analysts Say About FATE or VRTX?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 308.63%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $506.64 which suggests that it could grow by 6.01%. Given that Fate Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 VRTXVertex Pharmaceuticals, Inc.18 7 1 -
Is FATE or VRTX More Risky?
Fate Therapeutics, Inc. has a beta of 2.223, which suggesting that the stock is 122.341% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.
-
Which is a Better Dividend Stock FATE or VRTX?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or VRTX?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 20.08x versus 10.55x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.20.08x -- $1.7M -$32.3M VRTXVertex Pharmaceuticals, Inc.10.55x 33.68x $3.1B $1.1B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
75
BNAI alert for Jan 30
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
